The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Potential £7.5 million contract in the discussion stage by the sounds of that presentation:
17:41 - "Customer A came to us recently. They wanted to talk about a challenge study. Now we're combined we can actually talk to them about providing all of these capabilities to them, and suddenly a potential contract that we were looking at that might have been £3 million is now worth £7.5 million going forward. Not signed yet, but it's in that discussion stage."
In this presentation by CEO Trevor Phillips from January, he specifically states, at 6:09 "we don't currently work on Coronavirus". If that had changed, there would surely have been an announcement:
https://www.youtube.com/watch?v=9gVEiLrMsjg
It’s an Aim safe haven not a rocket. Weekend indices are now down 2.5% ( Dow, Hang song, Dax, Ftse ). DYOR
Blah blah doh!
Cathal seems far more cautious than some here: "he is very optimistic that, given the current Coronavirus outbreak, the clinic will certainly have a much higher utilisation in the weeks and months ahead." That sounds like a mere possibility of a modest increase in income.
Novacyt skyrocketed because they have produced a good testing kit for screening. That is urgent, US testing kits didn't work initially and their screening program seems to have failed at the first hurdle as they are using money-saving criteria to restrict testing, thereby potentially allowing the virus to pass unnoticed. Everyone is scrambling for kits, and Novacyt are the go-to company. Participating in stage 2 or stage 3 clinical trials on humans for one of the many vaccines currently being developed might boost ORPH a little bit, further down the line, but it doesn't sound like the same sort of moneyspinner. Still, it's not nothing, and every little helps the move towards profitability and to showcase aspects of the business for potential purchasers.
Orph sp still performing better than wider market with some companies being savaged this morning after days of drops.
Some bargains emerging atm. Golden time for investors sitting on some cash.
Quote:
"... vaccine development work had been almost like a Cinderella type industry in recent weeks but going forward it is clear that vaccine development is going to be one of the big growth markets in the years ahead.”
Quote:
"Open Orphan’s Executive Chairman Cathal Friel told ValueTheMarkets that the hVIVO merger “very much came at the right time”, adding: “Governments and pharmaceutical companies have not invested enough into novel vaccines for a long, long time and only now is it finally receiving a great deal of interest. Vaccine development work had been almost like a Cinderella type industry in recent weeks but going forward it is clear that vaccine development is going to be one of the big growth markets in the years ahead.”
Despite their evident expertise and the importance of bringing vaccines to market, scientists have traditionally struggled to attract the kind of capital needed to fully equip virology labs.
Open Orphan possesses the resources necessary to take advantage of this “gap in the market”. The company has access to a 24-bed high-quarantine facility at Queens. This is the only one of its kind in Europe, and is currently being used by pharmaceutical companies to test their vaccines against known viruses.
Traditionally, the clinic has only had a low utilisation of around 30%. However, Friel told investors at a recent shareholder presentation day that he is very optimistic that, given the current Coronavirus outbreak, the clinic will certainly have a much higher utilisation in the weeks and months ahead. The on-site viral laboratory can help companies to quickly and accurately analyse viruses, speeding up the vaccine development lifecycle."
Open Orphan primed to support coronavirus vaccine work after bringing in world-leading experts (ORPH)
https://www.valuethemarkets.com/2020/02/27/open-orphan-primed-to-support-coronavirus-vaccine-work-after-bringing-in-world-leading-experts-orph/